PSC Australia
  • Home
  • PSC
  • Resources
  • PSC Research
  • Rare Diseases
  • Contact Us

Scientific Research
This page is in a'blog' format with the latest scientific PSC research identified by Google Scholar, Readbyqmx.com and other sources added regularly.

Variation in Microbiome Composition and Stability for a Vancomycin Treated Primary Sclerosing Cholangitis Patient with Ulcerative Colitis Compared with Controls 

12/16/2015

0 Comments

 
Abstract


The bacterial composition of the human intestines contributes to much more than just digestion. In the inflammatory autoimmune conditions primary sclerosing cholangitis (PSC) and ulcerative colitis (UC), the microbiome may be, in some cases, a factor. To gain a better understanding of the composition and stability of the microbiome in a patient treated with vancomycin for PSC ... Please click here to read the full research article

Dubrovsky, Alanna (2015) "Variation in Microbiome Composition and Stability for a Vancomycin Treated Primary Sclerosing Cholangitis Patient with Ulcerative Colitis Compared with Controls," Symposium: Vol. 2: Iss. 1, Article 6.
Available at:
h p://digitalcommons.calpoly.edu/symposium/vol2/iss1/6 


0 Comments

Variation in Microbiome Composition and Stability for a Vancomycin Treated Primary Sclerosing Cholangitis Patient with Ulcerative Colitis Compared with Controls 

11/29/2015

0 Comments

 
Abstract 

The bacterial composition of the human intestines contributes to much more than just digestion. In the in- ammatory autoimmune conditions primary sclerosing cholangitis (PSC) and ulcerative colitis (UC), the microbiome may be, in some cases, a factor. To gain a better understanding of the composition and stability of the microbiome in a patient treated with vancomycin for PSC, terminal restriction fragment (TRF) analysis was performed on 13 controls and 1 patient, and 16s rRNA microbiome composition analyses were performed on 1 patient and 3 controls. Results showed similar levels of stability with surprising di erences in composition. Please click here to read the full text of the article




Dubrovsky, Alanna (2015) Symposium: Vol. 2: Iss. 1, Article 6.
DOI: 10.15368/symp.2015v2n1.2
Available at:
h p://digitalcommons.calpoly.edu/symposium/vol2/iss1/6 



0 Comments

Risk factors for recurrent primary sclerosing cholangitis after liver transplantation

11/26/2015

0 Comments

 
Abstract

Background & Aims
The association between primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD) is well recognised. However, the relationship between IBD and recurrent PSC (rPSC) is less well understood. We assessed the prevalence of rPSC and analysed the factors associated with rPSC post-liver transplantation and its influence on graft and patient survival.
Methods
This is a UK multicentre observational cohort study across six of the seven national liver transplant units. All patients undergoing a first liver transplant for PSC between January 1 1990 and December 31 2010 were included. Prospectively collected liver transplant data ... Please click here to read the full text of this article.

Reyna Ravikumar et al
Journal of Hepatology, November 2015, 63, 5, pp 1139-1146

0 Comments

Management of ulcerative colitis

11/14/2015

0 Comments

 
John M Fell, Rafeeq Muhammed, Chris Spray, Kay Crook, Richard K Russell, BSPGHAN IBD working group

Abstract
​
Ulcerative colitis (UC) in children is increasing. The range of treatments available has also increased too but around 1 in 4 children still require surgery to control their disease. An up-to-date understanding of treatments is essential for all clinicians involved in the care of UC patients to ensure appropriate and timely treatment while minimising the risk of complications and side effects.

Please click here to read the full article

Arch Dis Child doi:10.1136/archdischild-2014-307218

0 Comments

Recent advances in inflammatory bowel disease 

10/13/2015

0 Comments

 
David Al Dulaimi
Department of Gastroenterology, Alexandra Hospital, Redditch, UK 

This link will take you to a number of synopsis of recent papers considering the advances of knowledge in inflammatory bowel disease.

​Papers were prepared by:
Drs Luke Materacki and Ishfaq Ahmad, Alexandra Hospital, UK

Gastroenterol Hepatol Bed Bench 2014;8(4):313-315 

0 Comments

Consensus Statement:  SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease 

9/25/2015

0 Comments

 
INTRODUCTION

Patients with ulcerative colitis or Crohn’s colitis have an increased risk of colorectal cancer (CRC). Most cases are believed to arise from dysplasia, and surveillance colonos- copy therefore is recommended to detect dysplasia. Detec- tion of dysplasia traditionally has relied on both examination of the mucosa with targeted biopsies of visible lesions and extensive random biopsies to identify invisible dysplasia ... Please click here to read the full text version of this consensus statement.

Gastrointestinal Endoscopy, 2015, 81 (3)

Copyright a 2015 by the American Society for Gastrointestinal Endoscopy and American Gastroenterological Association
http://dx.doi.org/10.1016/j.gie.2014.12.009 
​
0 Comments

Outcome of patients with primary sclerosing cholangitis and ulcerative colitis undergoing colectomy

8/10/2015

0 Comments

 
Outcome of patients with primary sclerosing cholangitis and ulcerative colitis undergoing colectomy

Sombat Treeprasertsuk, Einar Björnsson, Emmanouil Sinakos, Emma Weeding, Keith D Lindor

AIM: 
To study the outcomes of primary sclerosing cholangitis (PSC) patients with ulcerative colitis (UC) undergoing colectomy.

METHODS: 
We identified 193 patients with PSC and UC undergoing colectomy at the Mayo Clinic (Rochester, MN, United States), between January 1, 1995 and December 31, 2008 using a computerized record system. Eighty-nine patients were excluded due to unclear diagnosis, liver transplantation prior to colectomy, age less than 18 years, inadequate follow-up data or known cases of cholangiocarcinoma. We retrospectively reviewed data from patient medical records. Clinical information, date of colectomy, preoperative and follow-up liver tests and pathological findings of the colon were reviewed. The Mayo risk score at baseline was calculated to obtain survival estimates for up to 4 years of follow-up.  ... Please click here to read the remainder of the abstract

World Journal of Gastrointestinal Pharmacology and Therapeutics 2013 August 6, 4 (3): 61-8
0 Comments

Malignancy in primary sclerosing cholangitis: Bile duct, liver, and colon

6/22/2014

0 Comments

 
Malignancy in primary sclerosing cholangitis: Bile duct, liver, and colon

Roger W. Chapman. Clinical Liver Disease Special Issue: Autoimmune Liver Disease, Part 4, 2014, Volume 3, Issue 4,  pages 83–85,

Abstract

As discussed in companion articles in CLD, the clinical course of large duct primary sclerosing cholangitis (PSC) is highly variable and unpredictable.[1, 2] Although the median survival from presentation to death or liver transplantation in symptomatic patients is approximately 10-12 years, 75% of asymptomatic patients will survive 15 years or more. A recent Dutch study has shown an overall median survival of 22 years in PSC patients.[3] . . . Please click here for the full article

An interview with the author and a video presentation of this article is available by clicking here.

0 Comments

Update on inflammatory bowel disease in patients with primary sclerosing cholangitis

6/22/2014

0 Comments

 
Update on inflammatory bowel disease in patients with primary sclerosing cholangitis

Christos Tsaitas, Anysia Semertzidou and Emmanouil Sinakos. World J Hepatol. 2014 April 27; 6(4): 1780-187. Published online 2014 April 27. doi: 10.4254/wjh.v6.i4.178.

Abstract

Patients with primary sclerosing cholangitis (PSC) complicated by inflammatory bowel disease (IBD) represent a distinct subset of patients with unique characteristics, which have serious clinical implications. The aim of this literature review was to shed light to the obscure clinical and molecular aspects of the two diseases combined utilizing current data available and putting issues of diagnosis and treatment into perspective. The prevalence of IBD, mainly ulcerative colitis in PSC patients is estimated to be 21%-80%, dependent on screening programs and nationality . . .  Please click here to read further

0 Comments

Normalization of Serum Alkaline Phosphatase in Primary Sclerosing Cholangitis Associated with Ulcerative Colitis 

4/21/2014

0 Comments

 

Normalization of Serum Alkaline Phosphatase in Primary Sclerosing Cholangitis Associated with Ulcerative Colitis 


Mitsuro Chiba, Hidehiko Tsuda, Satoko Tsuda, Masafumi Komatsu, Yasuo Horie, Hirohide Ohnishi

Abstract

Primary sclerosing cholangitis (PSC) is commonly associated with ulcerative colitis (UC). PSC progresses independently of UC ultimately resulting in liver failure. There is no established medi- cal treatment to improve the natural course of PSC. Normalization of serum alkaline phosphatase (ALP) in early stage might delay the progress of PSC. A 20-year-old female, had a sudden attack of right hypochondralgia with high fever and abnormal liver function tests without elevation of bili- rubin: ALP 478 IU/L, aspartate aminotransferase 360 IU/L, alanine aminotransferase 174 IU/L. Abnormal liver function tests returned to normal after the attacks. Morphological examinations initially indicated then confirmed a diagnosis of PSC. One month after displaying PSC symptoms administration of ursodeoxycholic acid was initiated. Similar attacks of cholangitis were repeated several times over the following two years. Even in the absence of these attacks, she always suf- fered postprandial hypochondralgia ... Full article available by clicking on the title

Copyright © 2014 by authors and Scientific Research Publishing Inc
This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/
0 Comments
<<Previous

    Research

    Every effort is taken to ensure the research presented is from reputable sources. 

    In order to ensure that copyright is not breached, only a small portion of the abstract is provided here. Clicking on the title will take you to the original journal, or site, where the abstract has been published. Most times only an abstract of an article is available as subscriptions are usually required. Occasionally a full text is made freely available.

    RSS Feed

    News & Updates Blog
    Glossary

    Archives

    December 2016
    September 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    August 2014
    July 2014
    June 2014
    April 2014
    March 2014


    Categories

    All
    Adolescence
    Adults
    Antibiotic
    Australia
    Australian
    Autoimmune Diseases
    Autoimmune Hepatitis
    Bezafibrate
    Bile Leak
    Biliary Strictures
    Cancer
    CCA Risk
    Children
    Cholangiocarcinoma
    Cholangitis
    Cholectomy
    Cholestatic Liver Disease
    Colectomy
    Colorectal Cancer
    Consensus Statement
    Crohn's Disease
    Diagnosis
    Drug Therapy
    Endoscopy
    Environmental Factors
    ERCP
    Fibroscan
    Genetics
    Genomes
    Genotypes
    Hepatic Cholestasis
    HLA
    IBD
    IgE Levels
    IgG4
    Inflammatory Bowel Disease
    Itching
    Leaky Gut
    Liver
    Liver Tests
    Liver Transplant
    Living Donor
    Management Of PSC
    MELD Score
    Microbiome
    Organ Donation
    Outcomes
    Paediatric Patients
    Paediatric PSC
    Patient And Graft Survival
    Pets
    Population
    Prognosis
    Pruritus
    PSC
    PSC/AIH
    Quality Of Life
    Questionnaire
    Recurrent PSC
    RPSC
    Sclerosing Cholangitis
    Scoring Systems
    Screening
    Staging
    Staging Systems
    Stem Cells
    Stenosis
    Terminal Restriction Fragment (TRF)
    Treatment
    Ulcerative Colitis
    Ultrasound
    Ultrasound Elastography
    Ursodeoxycholic Acid
    Vancomycin


    RSS Feed


    Page created 09.03.2014
    Updated: 09.04.2014
Disclaimer:  The information presented on this website is intended for information and educational purposes only, and is not intended to be a substitute for medical advice or information in any way. The information is not written by a medical practitioner, and as such it should never be used for diagnostic, treatment or management purposes. If you have questions regarding your medical needs, always seek the advice of your doctor, specialist or other appropriate and qualified health care professional.
This is a non-commercial website, designed and developed to provide relevant information to people living with Primary Sclerosing Cholangitis.
Wallpaper by Gaiam   www.gaiam.com.au

Full Disclaimer
Medical Disclaimer


Privacy & Cookie Policy


Powered by Create your own unique website with customizable templates.

BACK TO TOP

PSC-Australia.com.au
©2014 Health & Education Services | All Rights Reserved

© DivTag Templates Ltd | All Rights Reserved